Document Detail

Correlation between circulating adiponectin levels and coronary plaque regression during aggressive lipid-lowering therapy in patients with acute coronary syndrome: subgroup analysis of JAPAN-ACS study.
MedLine Citation:
PMID:  20684825     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: The Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) study demonstrated that aggressive lipid-lowering therapy with a statin resulted in a significant regression of coronary atherosclerotic plaques in patients with ACS. Adiponectin is an adipocyte-derived protein with anti-atherogenic properties. Here, we investigated the association between adiponectin levels and the change in the plaque volume in ACS patients.
METHODS: Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) was undertaken, followed by the initiation of statin treatment, in 238 patients with ACS. Follow-up IVUS was performed between 8 and 12 months after the PCI. The percent change in the plaque volume (%PV) in a non-culprit coronary artery segment was evaluated. The serum adiponectin and lipid parameters were measured both at baseline and at the follow-up.
RESULTS: At baseline, adiponectin was correlated positively with HDL-cholesterol and negatively correlated with triglyceride, but no correlation was observed with the PV. Adiponectin levels increased significantly from 7.8+/-4.6 microg/mL at baseline to 10.3+/-6.9 microg/mL at the 8-12 months follow-up. The increase in adiponectin was also associated with an increase of HDL-cholesterol and decrease of triglyceride, however, no significant correlation was observed with the %PV. A significantly higher incidence of major adverse cardiac events (MACE) was observed in patients with hypo-adiponectinemia at baseline. A multiple logistic regression analysis identified adiponectin as a significant independent predictor of MACE.
CONCLUSION: Adiponectin levels measured after PCI could serve as a marker of MACE in patients with ACS.
Taiki Ohashi; Rei Shibata; Takeshi Morimoto; Masaaki Kanashiro; Hideki Ishii; Satoshi Ichimiya; Takafumi Hiro; Katsumi Miyauchi; Yoshihisa Nakagawa; Masakazu Yamagishi; Yukio Ozaki; Takeshi Kimura; Hiroyuki Daida; Toyoaki Murohara; Masunori Matsuzaki
Related Documents :
2395495 - Homozygous familial hypercholesterolaemia: metabolic studies and treatment with ldl aph...
19476585 - National cholesterol education panel iii guidelines performance role in preventing myoc...
3169045 - Excess fatigue as a precursor of myocardial infarction.
11792135 - Effects of pravastatin on mortality in patients with and without coronary heart disease...
18598965 - Acute ischemia of canine interventricular septum produces asymmetric suppression of con...
16671335 - Relationships between echocardiographic findings, pulse wave velocity, and carotid athe...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2010-05-11
Journal Detail:
Title:  Atherosclerosis     Volume:  212     ISSN:  1879-1484     ISO Abbreviation:  Atherosclerosis     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-03     Completed Date:  2010-12-28     Revised Date:  2012-04-09    
Medline Journal Info:
Nlm Unique ID:  0242543     Medline TA:  Atherosclerosis     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  237-42     Citation Subset:  IM    
Copyright Information:
Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
Department of Cardiology, Yokkaichi Municipal Hospital, Yokkaichi, Japan.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Coronary Syndrome / blood,  drug therapy,  therapy*,  ultrasonography
Adiponectin / blood
Angioplasty, Balloon, Coronary / adverse effects*
Biological Markers / blood
Cardiovascular Diseases / blood,  etiology*
Cholesterol, HDL / blood
Coronary Vessels / drug effects*,  ultrasonography
Heptanoic Acids / therapeutic use*
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Logistic Models
Middle Aged
Odds Ratio
Prospective Studies
Pyrroles / therapeutic use*
Quinolines / therapeutic use*
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
Triglycerides / blood
Ultrasonography, Interventional
Reg. No./Substance:
0/ADIPOQ protein, human; 0/Adiponectin; 0/Biological Markers; 0/Cholesterol, HDL; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrroles; 0/Quinolines; 0/Triglycerides; 110862-48-1/atorvastatin; 147511-69-1/pitavastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Association of monocyte subsets with vulnerability characteristics of coronary plaques as assessed b...
Next Document:  Chronic infusion of salusin-alpha and -beta exerts opposite effects on atherosclerotic lesion develo...